Daiichi Sankyo : Announces Appointment of CxOs(129.8KB
March 31, 2023
Share
Press Release
Daiichi Sankyo Announces Appointment of CxOs
Tokyo, Japan - (March 31, 2023) - Daiichi Sankyo Company, Limited today announced the appointment of CxOs under the Global Management Structure effective from April 1, 2023.
1. CEO, COO
CxO
Name
Chief Executive Officer*
Sunao Manabe
(CEO)
Chief Operating Officer*
Hiroyuki Okuzawa
(COO)
2. CxO
As the heads of specific functions, CxOs will oversee the activities of our entire group from a management perspective, possess advanced and comprehensive expertise to their respective functional areas, and work to improve corporate value and address management issues.
CxO
Name
Head of Global Function
Chief Strategy Officer
Takashi Fukuoka
Head of Global Corporate Strategy*
(CStO)
Chief Financial Officer*
Koji Ogawa
Head of Global Corporate Planning &
(CFO)
Management*
Chief Digital Transformation Officer
Masahiko Ohtsuki
Head of Global DX*
(CDXO)
Chief Human Resources Officer
Takashi Matsumoto
Head of Global HR*
(CHRO)
General Counsel
Naoto Tsukaguchi
Head of Global Legal & IP*
(GC)
The appointment of these positions was announced in the press release "Daiichi Sankyo Announces Global Management Structure and Corporate Officers" on February 21, 2023
About Daiichi Sankyo
Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world- class science and technology for our purpose "to contribute to the enrichment of quality of life around the world." In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi
1
Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical need. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society." For more information, please visit www.daiichisankyo.com.
Media Contacts:
Japan:
Investor Relations Contact:
Koji Ogiwara
DaiichiSankyoIR@daiichisankyo.co.jp
Daiichi Sankyo Co., Ltd.
ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)
2
Attachments
Original Link
Original Document
Permalink
Disclaimer
Daiichi Sankyo Co. Ltd. published this content on 31 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 April 2023 12:59:10 UTC.
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).